Efficacy and safety of fulvestrant combined with abemaciclib in patients with hormone receptor-positive advanced breast cancer

Investigators used a real-world cohort to evaluate the efficacy and safety of fulvestrant plus abemaciclib in patients with HR+ advanced breast cancer. They compared these outcomes with those reported in the MONARCH 2 trial and found that the real-world cohort showed a higher overall response rate but a lower disease control rate. They concluded that these findings may reflect differences in prior treatments and baseline characteristics, and larger multicenter studies are needed for validation.